Sitagliptin phosphate is a Small Molecule owned by Merck & Co, and is involved in 128 clinical trials, of which 127 were completed, and 1 is ongoing.
Sitagliptin is a highly selective DPP-4 inhibitor exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones, thereby increasing the concentration and prolonging the action of these hormones. Incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), are released by the intestine throughout the day, and levels are increased in response to a meal. These hormones are rapidly inactivated by the enzyme, DPP-4. The incretins are part of an endogenous system involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic beta cells by intracellular signaling pathways involving cyclic AMP. GLP-1 also lowers glucagon secretion from pancreatic alpha cells, leading to reduced hepatic glucose production. By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner.
The revenue for Sitagliptin phosphate is expected to reach a total of $1bn through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Sitagliptin phosphate NPV Report.
Sitagliptin phosphate Overview
Sitagliptin phosphate (Januvia / Glactiv / Istavel / Tesavel / Xelevia / Ristaben / Fazique) is an compound belongs to the beta amino acid derivative acts as anti-diabetic agent. It is formulated as film coated tablets for oral route of administration. Sitagliptin phosphate is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is used in combination treatment with all oral medications for type 2 diabetes and insulin products.
Ono Pharmaceutical Overview
Ono Pharmaceutical focuses on the research, development, manufacture and sale of prescription pharmaceuticals and diagnostic reagents. Its product portfolio includes medicines for the treatment of type II diabetes, overactive bladder, osteoporosis, cancer, chemotherapy-induced nausea and vomiting, osteoporosis, Alzheimer’s disease, peripheral circulatory disorder, bronchial asthma and allergic rhinitis, among others. The company offers products in various formulations such as capsules, tablets, injections, patches, dry syrup and intravenous infusions. Ono Pharmaceutical has three manufacturing facilities; Joto Product Development Center, Yamaguchi Plant, and Fujiyama Plant. It offers products in the Americas, Europe, and Asia. Ono Pharmaceutical is headquartered in Osaka, Japan.
The company reported revenues of (Yen) JPY361,361 million for the fiscal year ended March 2022 (FY2022), an increase of 16.8% over FY2021. In FY2022, the company’s operating margin was 28.6%, compared to an operating margin of 31.8% in FY2021. In FY2022, the company recorded a net margin of 22.3%, compared to a net margin of 24.4% in FY2021. The company reported revenues of JPY109,979 million for the second quarter ended September 2022, an increase of 3.1% over the previous quarter.
Quick View – Sitagliptin phosphate
|Highest Development Stage|